甘露聚糖酶基因在毕赤酵母中的表达及酶学性质研究

采用PCR的方法,以枯草芽孢杆菌Bacillus subtilis基因组 DNA 为模板,克隆出甘露聚糖酶MAN的成熟肽编码序列,将其插入巴斯德毕赤酵母Pichia pastoris表达载体pPIC9K中,并位于α-因子信号肽序列的下游,获得重组质粒pPIC9K-MAN。重组质粒线性化后用聚乙二醇法导入毕赤酵母Pichia pastoris菌株GS115中,经大量筛选,获得高效分泌表达甘露聚糖酶的毕赤酵母工程菌株MAN22。将此菌株在5 L发酵罐中进行高密度发酵,测定酶活最高达1102IU /mL,同时对重组甘露聚糖酶的性质进行了初步研究。     

α-2b干扰素重组质粒的建立及在毕赤酵母中的表达

目的:采用基因工程手段构建基因工程菌表达α-2b干扰素。方法:根据毕赤酵母密码子嗜好性原理设计并合成α-2b干扰素基因序列,将其插入到毕赤酵母Pichia pastoris的分泌型表达质粒pPIC9K中,得到重组分泌表达质粒pPIC9K-IFNα-2b,并用电转化法转化P.pastoris GS115。筛选出整合型His Muts菌株,进一步用G418筛选获得高拷贝转化子,经5d诱导表达后SDS-PAGE检测。结果:菌落PCR和序列测定结果显示重组表达质粒已成功构建,SDS-PAGE结果显示目的蛋白已成功表达。结论:在毕赤酵母中成功表达α-2b干扰素。     

细极链格孢菌peaT2基因在毕赤酵母中的表达及蛋白功能确定

从细极链格孢菌表达文库获得阳性克隆子,序列分析表明,克隆的DNA片段中含有完整的开放阅读框架,将该基因命名为peaT2(GenBank登录号为EF212880)。用PCR法扩增peaT2基因的编码序列并亚克隆到毕赤酵母表达系统的表达载体pPIC9K上,得到重组质粒pPIC9K/peaT2。重组质粒经SacⅠ线性化后用电穿孔法导入到毕赤酵母(Pichia pastoris)GS115中,采用MD、G418-YPD平板和PCR法筛选Mut 表型,获得了分泌表达的重组毕赤酵母。随机挑取一菌株作为表达菌,用甲醇诱导PeaT2蛋白表达。SDS-PAGE及Western blot检测结果均表明PeaT2在毕赤酵母中成功地分泌表达。用peaT2基因的表达蛋白处理小麦种子,生物测定表明,表达蛋白能明显促进小麦的生长,具有蛋白激发子作用。     

人清道夫受体AII胞外部分在毕赤酵母(Pichia pastoris)中的分泌表达

清道夫受体A(SR-A)介导巨噬细胞无限制摄取修饰的低密度脂蛋白(mLDL)形成泡沫细胞,继而形成动脉粥样硬化病灶,在动脉粥样硬化的发生、发展过程中具有重要作用,被认为是治疗动脉粥样硬化的潜在靶点。本文应用RT-PCR方法扩增得到编码人Ⅱ型SR-A胞外部分(shSR-AII)的cDNA,将其克隆至毕赤酵母(Pichia pastoris)分泌表达载体pPIC9K构建重组表达质粒p9K-shSR-AII。将重组表达质粒线性化后,电转化毕赤酵母GS115,用原位双膜法筛选获得高表达shSR-AII的重组菌株GS115／p9K-shSR-AII。重组菌株经1％甲醇诱导,SDS-PAGE、Western blot分析表明shSR-AII获得了分泌表达。Ligand binding blot结果表明表达的shSR-AII具有与配基oxLDL结合的生物活性。U937泡沫细胞模型进一步表明shSR-AII可通过竞争性结合oxLDL来抑制泡沫细胞的形成,为以shSR-AII为靶点建立抗动脉粥样硬化药物筛选模型奠定了基础。     

重组人白细胞介素21在毕赤酵母中的分泌表达及活性分析

为了获得有活性的重组人白细胞介素21(rhIL-21),本研究建立了在毕赤酵母(Pichia pastoris)中分泌表达rhIL-21的技术。首先,通过RT-PCR从人外周血淋巴细胞中扩增IL-21cDNA,克隆到酵母表达载体pPIC9K中,构建了重组酵母表达载体pPIC9K-hIL21 cDNA;然后,线性化的载体转化毕赤酵母表达菌株GS115,经抗性梯度筛选获得了多拷贝重组酵母菌;加入甲醇诱导培养后,SDS-PAGE和Western blotting检测到培养液中有rhIL-21的分泌表达,相对分子量约为16kD,ELISA结果显示摇瓶表达量可达229.28mg/L;表达上清经阳离子交换介质SPSepharose Fast Flow纯化后,目的蛋白纯度达到95%。细胞增殖试验结果显示该rhIL-21联合刀豆蛋白A(ConA)对人淋巴细胞的增殖具有显著的促进作用。本研究首次成功在毕赤酵母表达系统中分泌表达了有生物活性的rhIL-21,为相关疾病免疫治疗的研究奠定了基础。     

用P.pastoris表达L-阿拉伯糖异构酶及其酶活性分析

目的:用毕赤酵母表达L-阿拉伯糖异构酶。方法:用PCR法扩增大肠杆菌的L-阿拉伯糖异构酶基因,构建含L-阿拉伯糖异构酶基因的毕赤酵母分泌型表达载体pPIC9K-ai。通过电转法将pPIC9K-ai转化毕赤酵母GS115基因组。先筛选出高G418抗性的克隆,然后再从高拷贝的克隆中筛选出高表达重组L-阿拉伯糖异构酶的重组子作为工程菌GS115(pPIC9K-ai)。结果:在甲醇诱导下,摇瓶发酵GS115(pPIC9K-ai)3d,分泌表达L-阿拉伯糖异构酶32 mg/L。结论:毕赤酵母表达的L-阿拉伯糖异构酶具有转化D-半乳糖为D-塔格糖的生物活性。每升GS115(pPIC9K-ai)发酵液能转化D-半乳糖生成30 mgD-塔格糖。     

OSF1在毕赤酵母菌中的分泌表达及其生物活性

为了研究人成骨细胞刺激因子(Human osteoblast-stimulating factor,OSF-1)的生物学活性,构建OSF-1高效毕赤酵母表达菌株并表达纯化具有生物活性的OSF-1。首先通过全基因人工合成的方法合成人osf-1基因,并克隆至毕赤酵母分泌表达载体pPIC9K,构建重组表达质粒pPIC9K/osf-1,线性化后电转化酵母宿主菌GS115,构建P.pastoris GS115/pPIC9K/osf-1,经MD、G418-YPD平板和PCR法筛选,获得多拷贝转化子。阳性表达菌株在25℃,经1%的甲醇诱导表达96 h,重组蛋白的表达量达到最大。经SDS-PAGE电泳分析所表达的重组蛋白约为18 kDa,与人成骨细胞刺激因子相符。表达上清经SP-Sephadex C-50离子交换层析进行纯化,得到纯度达98%以上的OSF-1。Western blotting鉴定该蛋白对人成骨细胞刺激因子抗体具有良好的抗原性。生物活性测定表明提纯的OSF-1能促进鼠成骨细胞MC3T3-E1的增殖和分化。利用重组毕赤酵母高效分泌表达了有生物活性的OSF-1,为进一步开展其抗骨质疏松活性研究及产业化开发奠定了基础。     

人67kD层粘连蛋白受体在毕赤酵母中的表达及活性分析

为实现人67kD层粘连蛋白受体(Human 67kD Laminin Receptor,67LR)蛋白的分泌表达,采用DNA重组技术将67LR cDNA片段插入分泌型酵母表达载体pPIC9K中,构建了相应的重组表达质粒pPIC9K-67LR并在GS115毕赤酵母菌株中表达,每升培养基经亲和层析可纯化目的蛋白12.56mg。纯化的目标蛋白能够与肺癌A549细胞竞争性结合其配体分子LN-1,具有相应的生物学活性,从而为深入研究人67LR的结构与功能奠定了基础。     

玉米赤霉烯酮降解酶毕赤酵母表达载体的构建及其表达

目的构建毕赤酵母表达载体pPIC9-ZEN-jjm,筛选高效分泌表达活性目的蛋白的菌株。方法克隆ZEN-jjm基因,经EcoRⅠ和NotⅠ双酶切连接至pPIC9中,电转化至毕赤酵母GS115。利用RDB培养基和甲醇诱导表达进行筛选。HPLC检测表达蛋白降解玉米赤霉烯酮的活性。结果测序表明ZEN-jjm成功插入pPIC9中,SDS-PAGE表明获得1株高效表达目的蛋白的重组酵母,其分子量约29 kDa。HPLC表明其能有效地降解玉米赤霉烯酮。结论玉米赤霉烯酮降解酶在毕赤酵母中获得了高效分泌表达。     

猪传染性胃肠炎病毒S基因B和C抗原位点片段在毕赤酵母中的表达

采用基因重组的方法构建了含有猪传染性胃肠炎病毒S基因B和C抗原位点片段的巴斯德毕赤酵母Pichiapastoris分泌型表达载体pPIC9K-ts,经线性化后采用电穿孔法将其导入毕赤酵母GS115中,大量筛选后获得高效表达外源蛋白的毕赤酵母工程菌株GS115/pPIC9K-ts。表达蛋白经Dot-ELISA检测具有良好的抗原性。本研究为TGE的血清学检测方法的建立提供了必要的物质基础。     

IL-6 trans-signaling system in intra-amniotic inflammation, preterm birth, and preterm premature rupture of the membranes

Classic IL-6 signaling is conditioned by the transmembrane receptor (IL-6R) and homodimerization of gp130. During trans-signaling, IL-6 binds to soluble IL-6R (sIL-6R), enabling activation of cells expressing solely gp130. Soluble gp130 (sgp130) selectively inhibits IL-6 trans-signaling. To characterize amniotic fluid (AF) IL-6 trans-signaling molecules (IL-6, sIL-6R, sgp130) in normal gestations and pregnancies complicated by intra-amniotic inflammation (IAI), we studied 301 women during second trimester (n = 39), third trimester (n = 40), and preterm labor with intact (n = 131, 85 negative IAI and 46 positive IAI) or preterm premature rupture of membranes (PPROM; n = 91, 61 negative IAI and 30 positive IAI). ELISA, Western blotting, and real-time RT-PCR were used to investigate AF, placenta, and amniochorion for protein and mRNA expression of sIL-6R, sgp130, IL-6R, and gp130. Tissues were immunostained for IL-6R, gp130, CD15(+) (polymorphonuclear), and CD3(+) (T cell) inflammatory cells. The ability of sIL-6R and sgp130 to modulate basal and LPS-stimulated release of amniochorion matrix metalloprotease-9 was tested ex vivo. We showed that in physiologic gestations, AF sgp130 decreases toward term. AF IL-6 and sIL-6R were increased in IAI, whereas sgp130 was decreased in PPROM. Our results suggested that fetal membranes are the probable source of AF sIL-6R and sgp130. Immunohistochemistry and RT-PCR revealed increased IL-6R and decreased gp130 expression in amniochorion of women with IAI. Ex vivo, sIL-6R and LPS augmented amniochorion matrix metalloprotease-9 release, whereas sgp130 opposed this effect. We conclude that IL-6 trans-signaling molecules are physiologic constituents of the AF regulated by gestational age and inflammation. PPROM likely involves functional loss of sgp130.     

Expression and immunogenicity of the extracellular domain of the human immunodeficiency virus type 1 envelope glycoprotein, gp160.

The envelope glycoprotein of human immunodeficiency virus type 1 is synthesized as a precursor, gp160, that subsequently is cleaved to yield mature gp120 and gp41. In these studies, the gene encoding gp160 was mutagenized so as direct the synthesis of a truncated protein consisting of the extracellular domains of both gp120 and gp41. The variant protein, termed sgp160, consisted of 458 amino acids of gp120 and 172 amino acids of gp41. To facilitate protein purification, the normal polyglycoprotein processing site between gp120 and gp41 was deleted through the use of site-directed mutagenesis. This allowed for the synthesis of a molecule that could be purified by affinity chromatography, using acid elution, without dissociation of the gp120 polypeptide from the gp41 polypeptide. The conformation of the sgp160 variant appeared to be functionally relevant, as reflected by its ability to bind to CD4 with an affinity comparable to that of the variant rgp120. The structure of the sgp160-containing polypeptide differed from that of rgp120 in that it tended to form high-molecular-weight aggregates that could be dissociated to monomers and dimers in the presence of reducing agents. Antibodies against the sgp160 protein reacted with authentic virus-derived gp160, gp120, and gp41; neutralized viral infectivity; and inhibited the binding of rgp120 to CD4. Rabbit antibodies to the sgp160 protein differed from those raised against rgp120 in that they were enriched for populations that blocked CD4 binding but did not prevent human immunodeficiency virus type 1-induced syncytium formation.     

Interleukine-6 (IL-6) synthesis and gp130 expression by human pericardium.

Growing evidence shows that cytokines of the IL-6 family play an important regulatory role in heart physiology such as inducing cardiomyocyte hypertrophy. The purpose of this study was to see if IL-6 and its soluble receptors (sIL-6R and sgp130) could be detected in pericardial fluids, and to see if they are produced by the pericardium. We report that human pericardial fluid from patients with coronary pathologies contained IL-6, sIL-6R, and sgp130. However, the levels present in sera and pericardial fluid did not correlate, which suggests local production. This observation was confirmed by in vitro studies demonstrating massive IL-6 production by cultured pericardial samples, which could be strongly inhibited by methylprednisolone. RT-PCR studies revealed that IL-6 was weakly expressed in fresh tissues and strongly induced after culture. In situ hybridisation and immunohistochemical analysis showed that IL-6 and gp130 were mainly present in mesothelial cells. sIL-6R and sgp130 were also produced by pericardium in vitro, and their synthesis was upregulated by methylprednisolone. Taken together, these results demonstrate that IL-6 is present in pericardial fluid and that its presence could be due to synthesis by pericardial tissue. In vitro studies suggest that IL-6 production by this tissue could be strongly induced and regulated. A potential paracrine role of these factors in cardiomyocyte functions in normal or pathological conditions is discussed.     

Ubiquitous 9-O-acetylation of sialoglycoproteins restricted to the Golgi complex

9-O-Acetylation of sialic acid is known as a cell type-specific modification of secretory and plasma membrane glycoconjugates of higher vertebrates with important functions in modulating cell-cell recognition. Using a recombinant probe derived from influenza C virus hemagglutinin, we discovered 9-O-acetylated protein in the Golgi complex of various cell lines, most of which did not display 9-O-acetylated sialic acid on the cell surface. All cell lines expressed a sulfated glycoprotein of 50 kDa (sgp50) carrying 9-O-acetylated sialic acids, which was used as a model substrate. Like gp40, the major receptor for influenza C virus of Madin-Darby canine kidney I cells, sgp50 is 9-O-acetylated on O-linked glycans. However, gp40 was not 9-O-acetylated when expressed in Madin-Darby canine kidney II or COS-7 cells. The results demonstrate the existence of two 9-O-acetylation machineries for O-glycosylated proteins with distinct substrate specificities. The widespread occurrence of 9-O-acetylated protein in the Golgi furthermore suggests an additional intracellular role for this modification.     

Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d

DNA vaccines expressing the envelope (Env) protein of the human immunodeficiency virus have been relatively ineffective at generating high-titer, long-lasting, neutralizing antibodies in a variety of animal models. In this study, the murine and human homologues of the complement component, C3d, were used in a DNA vaccine to enhance the titers of antibody to Env. Initially, plasmids expressing a secreted form of Env (sgp120) fused to one, two, or three copies of the murine homologue of C3d (mC3d) were constructed. Mice were inoculated with four vaccinations of DNA or two DNA vaccinations, followed by two boosts of affinity-purified gp120 protein. Analyses of titers demonstrated that multiple copies of mC3d coupled to sgp120 induced long-lasting, high-titer anti-Env antibody. Priming mice with sgp120-mC3d-DNA, followed by inoculation of purified gp120 protein, elicited the strongest antibody titers; however, the avidity maturation of the antibody was accelerated in the mice inoculated with sgp120-mC3d(3)-DNA. In addition, DNAs expressing sgp120 fused to three copies of the human homologue of C3d (hC3d(3)) efficiently enhanced the anti-Env antibody in rabbits. Lastly, antisera from both mice and rabbits vaccinated with DNA expressing sgp120-C3d(3) elicited higher titers of neutralizing antibody than did nonfused forms of Env. These results indicate that C3d, conjugated to sgp120, enhances the antibody responses to Env compared to non-C3d fused forms of Env, and this approach may be one way to overcome the poor ability of DNA vaccines to generate antibodies to Env.     

人睫状神经营养因子在大肠杆菌和毕赤酵母中的表达和生物活性测定

The recombinant human ciliary neurotrophi factor(hCNTF)expressed in E.coli aggregatedas inclusion bodies and refolding procedure was necessary to obtine the active protein.To overcome the disadvantage,we cloned hcntf gene into yeast expression plasmid pPIC9K and collected the plasmid pPIC9K-hcntf.Plasmid pPIC9K-hcntf was transformed into yeast Pichia pastoris GS115,and screened on G418-SD plates.The transformants with high copies of hcntf gene were inoculated into BMMY media and induced with 0.5% methanol.The recombinant hCNTF was secreted into the media.The amount of hCNTF in the supernatant was about 10 mg/L when incubated in the conical flasks and reached up to 60 mg/L under fed-batch condition in 15 L fermentator.The recombinant hCNTF expressed in E.coli was renatured as the control.The neonatal rat dorsal root ganglion assay showed that proteins expressed in both systems have the activity of promoting the growth of neuron axons.The phenomenon can be observed with only 3 μg hCNTF expressed in yeast present,which indicates that hCNTF was successfully expressed in Pichia pastoris and has a relatively high activity.     

血管生成抑制因子K4K5 Cdna基因的克隆及其在毕赤酵母中的表达

应用PCR方法,扩增人纤溶酶原cDNA基因中K4K5 cDNA片段,与酵母表达载体pPIC9K重组,获得表达质凿p9kkk-18。该质粒转化毕赤酵母菌GS115,用G418－YPD筛选高拷贝表型,PCR筛选K4K5 cDNA与酵母染色体整全形成的阳性克隆,阳性克隆用甲醇诱导表达。表达产物r-K4K5分子量约21.5kD,占分泌总蛋白80％以上,产物浓度为150－250mg/L。初步纯化产物抑制牛毛细血管内皮（BCE）细胞增殖与鸡胚绒毛尿囊膜（CAM）新生血管生成。     

Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses.

Signal transduction in response to interleukin-6 (IL-6) requires binding of the cytokine to its receptor (IL-6R) and subsequent homodimerization of the signal transducer gp130. The complex of IL-6 and soluble IL-6R (sIL-6R) triggers dimerization of gp130 and induces responses on cells that do not express membrane bound IL-6R. Naturally occurring soluble gp130 (sgp130) can be found in a ternary complex with IL-6 and sIL-6R. We created recombinant sgp130 proteins that showed binding to IL-6 in complex with sIL-6R and inhibited IL-6/sIL-6R induced proliferation of BAF/3 cells expressing gp130. Surprisingly, sgp130 proteins did not affect IL-6 stimulated proliferation of BAF/3 cells expressing gp130 and membrane bound IL-6R, indicating that sgp130 did not interfere with IL-6 bound to IL-6R on the cell surface. Additionally, sgp130 partially inhibited proliferation induced by leukemia inhibitory factor (LIF) and oncostatin M (OSM) albeit at higher concentrations. Recombinant sgp130 protein could be used to block the anti-apoptotic effect of sIL-6R on lamina propria cells from Crohn disease patients. We conclude that sgp130 is the natural inhibitor of IL-6 responses dependent on sIL-6R. Furthermore, recombinant sgp130 is expected to be a valuable therapeutic tool to specifically block disease states in which sIL-6R transsignaling responses exist, e.g. in morbus Crohn disease.     

Interleukin-6 receptor signaling. II. Bio-availability of interleukin-6 in serum.

Interleukin-6 (IL-6) is used as a growth factor by various tumor cells. It binds to a gp80 specific receptor (IL-6R) and then to a gp130 transducing chain. Both receptor chains are released as soluble functional proteins which circulate in biological fluids. With a view to studying the physiological role of these soluble receptors, both proteins were purified from human plasma. Surface plasmon resonance was used to measure the kinetic constants of equilibria between IL-6 and natural sIL-6R, and between the IL-6/sIL-6R complex and soluble gp130. Kd values were found to be 0. 9 and 2.3 nM respectively. Soluble natural IL-6R and gp130 were also found to interact with a Kd of 2.8 nM in the absence of IL-6. By using these Kd values, a mathematical simulation predicted that 1) within a large range of IL-6, sIL-6R and sgp130 concentrations, free IL-6 represents 30% of the total circulating cytokine, 2) sIL-6R overconcentrations lead to dramatic changes of the concentration of free IL-6, 3) increased concentrations of sgp130 should produce an efficient buffering effect on the IL-6/sIL-6R complex without incidence on the level of free IL-6. According to this model, the IL-6/sIL-6R complex appears to be an important support of IL-6 signaling in the most commonly encountered in vivo situations. The concentration of this complex is directly under the control of the concentration of sIL-6R; its bio-availability should be efficiently buffered by increased sgp130 concentrations.